| Hormone receptor positive breast cancer
Faslodex vs Trodelvy
Side-by-side clinical, coverage, and cost comparison for hormone receptor positive breast cancer.Deep comparison between: Faslodex vs Trodelvy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrodelvy has a higher rate of injection site reactions vs Faslodex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trodelvy but not Faslodex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Faslodex
Trodelvy
At A Glance
IM injection
Once monthly
Estrogen receptor antagonist
IV infusion
Once weekly (Days 1 and 8 of 21-day cycles)
Trop-2-directed antibody-drug conjugate
Indications
- Hormone receptor positive breast cancer
- Triple Negative Breast Neoplasms
- Hormone receptor positive breast cancer
Dosing
Hormone receptor positive breast cancer - Monotherapy 500 mg IM as two 5 mL injections into the gluteal area on Days 1, 15, 29, and once monthly thereafter; reduce to 250 mg as one 5 mL injection for moderate hepatic impairment (Child-Pugh class B) on the same schedule.
Hormone receptor positive breast cancer - Combination with palbociclib, abemaciclib, or ribociclib 500 mg IM as two 5 mL injections into the gluteal area on Days 1, 15, 29, and once monthly thereafter.
Triple Negative Breast Neoplasms, Hormone receptor positive breast cancer 10 mg/kg IV infusion once weekly on Days 1 and 8 of 21-day treatment cycles until disease progression or unacceptable toxicity; first infusion over 3 hours, subsequent infusions over 1 to 2 hours if prior infusions were tolerated.
Contraindications
- Known hypersensitivity to fulvestrant or any of its components
- Previous severe hypersensitivity reaction to TRODELVY
Adverse Reactions
Most common (>=10%) Arthralgia, hot flash, fatigue, nausea, injection site pain, bone pain
Serious Hepatic enzyme elevations (Grade 3-4), injection site reactions including sciatica and neuropathic pain
Postmarketing Vaginal bleeding, elevated bilirubin, elevated gamma GT, hepatitis, liver failure
Most common (>=25%) Decreased leukocyte count, decreased neutrophil count, decreased hemoglobin, diarrhea, nausea, decreased lymphocyte count, fatigue, alopecia, constipation, increased glucose, decreased albumin, vomiting, decreased appetite, decreased creatinine clearance, increased alkaline phosphatase, decreased magnesium, decreased potassium, decreased sodium
Serious Neutropenia, febrile neutropenia, diarrhea, pneumonia, abdominal pain, colitis, neutropenic colitis, vomiting, respiratory failure, septic shock
Pharmacology
Fulvestrant is an estrogen receptor (ER) antagonist that competitively binds to the ER with affinity comparable to estradiol, downregulates ER protein in human breast cancer cells, and inhibits growth of both estrogen-sensitive and tamoxifen-resistant cell lines with no agonist effects.
Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate in which the humanized anti-Trop-2 antibody sacituzumab delivers SN-38, a topoisomerase I inhibitor, into Trop-2-expressing cancer cells, where SN-38 prevents re-ligation of topoisomerase I-induced single-strand breaks, leading to DNA damage, apoptosis, and cell death.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Faslodex
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Trodelvy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Faslodex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Trodelvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Faslodex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Trodelvy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Bladder Cancer (Federal Healthcare Program): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FaslodexView full Faslodex profile
TrodelvyView full Trodelvy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.